SCHEMBL5422989

SCHEMBL5422989

Cc1ccc(C(=O)NCC2CCOC2)cn1

nearest known ligand 0.59

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 9/20 0.59
GABRA5 P31644 2/20 0.57
GABRA1 P14867 1/20 0.51
EGLN1 Q9GZT9 2/20 0.50
KDM4E B2RXH2 1/20 0.50
HDAC1 Q13547 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
BRAF P15056 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5420230 0.85 GABRA1 (0.60) GABRA5GABRA1KDM4EHDAC1HDAC6
SCHEMBL5433116 0.83 MMP13 (0.56) NAMPTGABRA1KDM4EHDAC1HDAC6
SCHEMBL22859047 0.78 NAMPT (0.58) NAMPTHDAC1
SCHEMBL22859045 0.78 NAMPT (0.58) NAMPTHDAC1
SCHEMBL22922423 0.78 NAMPT (0.58) NAMPTHDAC1
SCHEMBL15529281 0.78 NAMPT (0.58) NAMPTKDM4E
SCHEMBL5422109 0.78 KMT2A (0.71) KDM4E
SCHEMBL5424557 0.78 KMT2A (0.71) KDM4E
SCHEMBL280094 0.78 KMT2A (0.71) KDM4E
SCHEMBL3866086 0.78 NAMPT (0.43) NAMPTGABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-08 US claimed
EP-1551404-A2 METHOD OF INHIBITING ANGIOGENESIS Abbott Laboratories (US) 2005-07-13 EP claimed
US-20040116479-A1 Method of inhibiting angiogenesis ABBOTT LABORATORIES 2004-06-17 US claimed
WO-2004032908-A9 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LAB (US) 2004-05-27 WO claimed
WO-2004032908-A2 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LABORATORIES (US) 2004-04-22 WO claimed
US-20040067985-A1 Method of inhibiting angiogenesis ABBOT LABORATORIES 2004-04-08 US claimed
US-20070043089-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-22 US disclosed
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-08 US disclosed
EP-1551404-A2 METHOD OF INHIBITING ANGIOGENESIS Abbott Laboratories (US) 2005-07-13 EP disclosed
US-20040116479-A1 Method of inhibiting angiogenesis ABBOTT LABORATORIES 2004-06-17 US disclosed
WO-2004032908-A9 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LAB (US) 2004-05-27 WO disclosed
WO-2004032908-A2 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LABORATORIES (US) 2004-04-22 WO disclosed
US-20040067985-A1 Method of inhibiting angiogenesis ABBOT LABORATORIES 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS PGF, VEGFA, FLT4 NAMPT 281/4885GABRA5 3789/4885GABRA1 3682/4885
US-20070043089-A1 METHOD OF INHIBITING ANGIOGENESIS PGF, VEGFA, FLT4 NAMPT 281/4885GABRA5 3789/4885GABRA1 3682/4885
US-20040067985-A1 Method of inhibiting angiogenesis VEGFA, PGF, FLT4 NAMPT 424/4885GABRA5 4299/4885GABRA1 3945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.